{
  "source": "PA-Notification-Bylvay.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1367-4\nProgram Prior Authorization/Notification\nMedication Bylvay™ (odevixibat)\nP&T Approval Date 9/2021, 9/2022, 8/2023, 8/2024\nEffective Date 11/1/2024\n1. Background:\nBylvay (odevixibat) is an ileal bile acid transporter inhibitor indicated for the treatment of\npruritis in patients aged 3 months or older with progressive familial intrahepatic cholestasis\n(PFIC). Bylvay is also indicated for the treatment of pruritis in patients 12 months of age and\nolder with Alagille syndrome (ALGS).\nLimitation of Use:\nBylvay may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11\nvariants resulting in non-functional or complete absence of bile salt export pump protein (BSEP-\n3).\n2. Coverage Criteriaa:\nA. Progressive Familial Intrahepatic Cholestasis\n1. Initial Authorization\na. Bylvay will be approved based upon both of the following criteria:\n(1) Diagnosis of progressive familial intrahepatic cholestasis (PFIC)\n-AND-\n(2) Patient is experiencing pruritus associated with PFIC.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Bylvay will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Bylvay therapy\nAuthorization will be issued for 12 months.\nB. Alagille Syndrome\n1. Initial Authorization\na. Bylvay will be approved based upon both of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(1) Diagnosis of Alagille syndrome (ALGS).\n-AND-\n(2) Patient is experiencing pruritus associated with ALGS.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Bylvay will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Bylvay therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement prog",
    " months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. Reference:\n1. Bylvay™ [package insert]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; February 2024.\nProgram Prior Authorization/Notification - Bylvay™ (odevixibat) Notification\nChange Control\n9/2021 New program\n9/2022 Annual review with no changes to criteria. Added state mandate\nfootnote.\n8/2023 Added coverage criteria for new ALGS indication. Updated reference.\n8/2024 Annual review. Updated initial authorization durations to 12 months.\nUpdated background and reference.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}